Viracta Therapeutics Statistics
Total Valuation
VIRX has a market cap or net worth of $8.35 million. The enterprise value is $4.13 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, before market open.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
VIRX has 39.74 million shares outstanding. The number of shares has increased by 1.99% in one year.
| Current Share Class | 39.74M |
| Shares Outstanding | 39.74M |
| Shares Change (YoY) | +1.99% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 2.75% |
| Owned by Institutions (%) | 14.68% |
| Float | 28.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.76
| Current Ratio | 0.76 |
| Quick Ratio | 0.74 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.84 |
Financial Efficiency
Return on equity (ROE) is -370.13% and return on invested capital (ROIC) is -89.60%.
| Return on Equity (ROE) | -370.13% |
| Return on Assets (ROA) | -66.76% |
| Return on Capital (ROIC) | -89.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.08M |
| Employee Count | 40 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.16% in the last 52 weeks. The beta is 0.18, so VIRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -52.16% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 0.50 |
| Relative Strength Index (RSI) | 60.68 |
| Average Volume (20 Days) | 3,957,727 |
Short Selling Information
The latest short interest is 1.58 million, so 3.96% of the outstanding shares have been sold short.
| Short Interest | 1.58M |
| Short Previous Month | 2.10M |
| Short % of Shares Out | 3.96% |
| Short % of Float | 5.49% |
| Short Ratio (days to cover) | 1.85 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -47.21M |
| Pretax Income | -47.99M |
| Net Income | -43.29M |
| EBITDA | -46.77M |
| EBIT | -47.21M |
| Earnings Per Share (EPS) | -$1.10 |
Full Income StatementBalance Sheet
The company has $21.13 million in cash and $16.91 million in debt, giving a net cash position of $4.22 million or $0.11 per share.
| Cash & Cash Equivalents | 21.13M |
| Total Debt | 16.91M |
| Net Cash | 4.22M |
| Net Cash Per Share | $0.11 |
| Equity (Book Value) | -6.62M |
| Book Value Per Share | -0.17 |
| Working Capital | -6.77M |
Full Balance SheetCash Flow
| Operating Cash Flow | -34.80M |
| Capital Expenditures | n/a |
| Free Cash Flow | -34.80M |
| FCF Per Share | -$0.88 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |